Capricor Therapeutics News and Activities
Presence
Capricor Therapeutics is a biotechnology company that develops cell and exosome therapies. Its products and research services support patients with rare diseases and healthcare partners in regenerative medicine.
Capricor Therapeutics products and services overview:
- Cell therapy
- Exosome therapy
- Rare disease treatments
- Research services
Revenue: ~$27 million
Employees: 110
Headquarters: San Diego, United States (USA)
Capricor Therapeutics is one of the...
Capricor Therapeutics is a company listed under the stock ticker CAPR (US).
Executives
View the org chart displaying its 26 main executives
Most searched biographies at Capricor Therapeutics
- Linda Marban, President, Chief Executive Officer, Director
- Karimah Es Sabar, Director
- Philip Gotwals, Director
Popular executive movements at Capricor Therapeutics
- Michael Maurer has joined the company as Chief Commercial Officer (posted on June 1 2026).
Create your alert
to follow the executive moves at Capricor Therapeutics.
Biotechnology
Capricor Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Capricor Therapeutics
- Capricor Therapeutics to Present at Upcoming Investor Conferences
- Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
- Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
- Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
- Press Releases
- Capricor Therapeutics Announces Proposed Public Offering of Common Stock
- Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
- Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
- View more press releases Close
Social media about Capricor Therapeutics
- Capricor Therapeutics on Wikipedia, Google News & Yahoo Finance
- Capricor Therapeutics on LinkedIn, X (Twitter) & YouTube
